Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2008 Apr;5(2):164–180. doi: 10.1016/j.nurt.2007.12.001

Current status of symptomatic medical therapy in Parkinson’s disease

Stewart A Factor 1,✉
PMCID: PMC5084161  PMID: 18394561

Summary

Symptomatic medical therapies for Parkinson’s disease (PD) have been disease modifying and have led to improvement in daily function, quality of life, and survival. For 40 years, these therapies have been primarily dopaminergic, and currently include the dopamine (DA) precursor levodopa (LD), DA agonists, catechol-O-methyltransferase (COMT) inhibitors, and monoamine oxidase (MAO) inhibitors. The roles of all these classes of agents have evolved, with significant changes occurring since the early 2000s. This article reviews the current literature for each of these classes of drugs, with a focus on efficacy and place in the therapeutic scheme. Levodopa is no longer considered to be toxic and, thus, its early use is not only appropriate but recommended. Ergot agonists are no longer in use, and new agents administered in patch form or subcutaneous injections have been approved. The COMT inhibitor tolcapone, with its significant efficacy, has been reintroduced, and two new MAO inhibitors have been approved. Selected safety issues are discussed, including the incidence of melanoma in relation to LD; pathological gambling and DA agonists; hepatic toxicity of tolcapone; and the tyramine or so-called cheese reaction with MAO B inhibitors. The article closes with a discussion of future directions and new drugs under development.

Key Words: Parkinson’s disease, symptomatic therapy, levodopa, dopamine agonists, COMT inhibitors, MAO inhibitors

References

  • 1.Factor SA. Levodopa. In: Pahwa R, Lyons KE, editors. Handbook of Parkinson’s disease. 4th ed. New York: Informa Healthcare; 2007. pp. 309–334. [Google Scholar]
  • 2.Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids. 2002;23:65–70. doi: 10.1007/s00726-001-0111-9. [DOI] [PubMed] [Google Scholar]
  • 3.Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord. 2002;17:501–508. doi: 10.1002/mds.10115. [DOI] [PubMed] [Google Scholar]
  • 4.Agid Y. Levodopa: is toxicity a myth? Neurology. 1998;50:858–863. doi: 10.1212/wnl.50.4.858. [DOI] [PubMed] [Google Scholar]
  • 5.Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson’s disease: a consensus meeting. Mov Disord. 1999;14:911–913. doi: 10.1002/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  • 6.Cotzias GC, Van Woert M, Shiffer L. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276:374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
  • 7.Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-DOPA. N Engl J Med. 1969;280:337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  • 8.Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21:343–354. doi: 10.1001/archneur.1969.00480160015001. [DOI] [PubMed] [Google Scholar]
  • 9.Kapp W. The history of drugs for the treatment of Parkinson’s disease. J Neural Transm. 1992;38:1–6. [PubMed] [Google Scholar]
  • 10.Rinne UK, Molsa P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology. 1979;29:1584–1589. doi: 10.1212/wnl.29.12.1584. [DOI] [PubMed] [Google Scholar]
  • 11.Rinne UK, Birket-Smith E, Dupont E, et al. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson’s disease: a controlled clinical trial. J Neurol. 1975;211:1–9. doi: 10.1007/BF00312459. [DOI] [PubMed] [Google Scholar]
  • 12.Goetz CG, Tanner CM, Shannon KM, et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson’s disease patients with and without motor fluctuations. Neurology. 1988;38:1143–1146. doi: 10.1212/wnl.38.7.1143. [DOI] [PubMed] [Google Scholar]
  • 13.Jankovic J, Schwartz K, Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989;4:303–309. doi: 10.1002/mds.870040403. [DOI] [PubMed] [Google Scholar]
  • 14.Factor SA, Sanchez-Ramos JR, Weiner WJ, Ingenito AM. Efficacy of Sinemet CR4 in subgroups of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1989;52:83–88. doi: 10.1136/jnnp.52.1.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Factor SA. Parkinson’s Disease: initial treatment with levodopa or dopamine agonists. Curr Treat Options Neurol. 2001;3:479–493. doi: 10.1007/s11940-001-0011-z. [DOI] [PubMed] [Google Scholar]
  • 16.Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–458. doi: 10.1002/mds.1090. [DOI] [PubMed] [Google Scholar]
  • 17.Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord. 1987;2:73–91. doi: 10.1002/mds.870020201. [DOI] [PubMed] [Google Scholar]
  • 18.Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990. Arch Neurol. 2006;63:205–209. doi: 10.1001/archneur.63.2.205. [DOI] [PubMed] [Google Scholar]
  • 19.Fahn S, Oakes D, Shoulson I, Parkinson Study Group et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508. doi: 10.1056/NEJMoa033447. [DOI] [PubMed] [Google Scholar]
  • 20.Fahn S, Parkinson Study Group Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol. 2005;252(Suppl 4):iv37–iv42. doi: 10.1007/s00415-005-4008-5. [DOI] [PubMed] [Google Scholar]
  • 21.Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–1491. doi: 10.1056/NEJM200005183422004. [DOI] [PubMed] [Google Scholar]
  • 22.Holloway RG, Shoulson I, Fahn S, et al. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044–1053. doi: 10.1001/archneur.61.7.1044. [DOI] [PubMed] [Google Scholar]
  • 23.Parkinson Study Group Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931–1938. doi: 10.1001/jama.284.15.1931. [DOI] [PubMed] [Google Scholar]
  • 24.Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58:11–17. doi: 10.1212/wnl.58.1.11. [DOI] [PubMed] [Google Scholar]
  • 25.Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat Disord. 2003;9:321–327. doi: 10.1016/S1353-8020(03)00040-3. [DOI] [PubMed] [Google Scholar]
  • 26.Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer. 2005;92:201–205. doi: 10.1038/sj.bjc.6602279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S. Treatment with levodopa and risk for malignant melanoma. Mov Disord. 2007;22:1252–1257. doi: 10.1002/mds.21397. [DOI] [PubMed] [Google Scholar]
  • 28.Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology. 2004;63:886–891. doi: 10.1212/01.wnl.0000137886.74175.5a. [DOI] [PubMed] [Google Scholar]
  • 29.Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023–2031. doi: 10.1001/jama.288.16.2023. [DOI] [PubMed] [Google Scholar]
  • 30.Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C-->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology. 2002;59:529–536. doi: 10.1212/wnl.59.4.529. [DOI] [PubMed] [Google Scholar]
  • 31.Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002;346:476–483. doi: 10.1056/NEJMoa011613. [DOI] [PubMed] [Google Scholar]
  • 32.Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson’s disease. Acta Neurol Scand. 2003;108:66–67. doi: 10.1034/j.1600-0404.2003.00135.x. [DOI] [PubMed] [Google Scholar]
  • 33.O’Suilleabhain PE, Bottiglieri T, Dewey RB, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson’s disease. Mov Disord. 2004;19:1403–1408. doi: 10.1002/mds.20253. [DOI] [PubMed] [Google Scholar]
  • 34.Muller T, Kuhn W. Tolcapone decreases plasma levels of Sadenosyl-l-homocysteine and homocysteine in treated Parkinson’s disease patients. Eur J Clin Pharmacol. 2006;62:447–450. doi: 10.1007/s00228-006-0132-0. [DOI] [PubMed] [Google Scholar]
  • 35.Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord. 2005;11:253–256. doi: 10.1016/j.parkreldis.2005.01.007. [DOI] [PubMed] [Google Scholar]
  • 36.Bostantjopoulou S, Katsarou Z, Frangia T, et al. Endothelial function markers in parkinsonian patients with hyperhomocysteinemia. J Clin Neurosci. 2005;12:669–672. doi: 10.1016/j.jocn.2004.09.012. [DOI] [PubMed] [Google Scholar]
  • 37.Factor SA. Dopamine agonists. Med Clin North Am. 1999;83:415–443. doi: 10.1016/S0025-7125(05)70112-7. [DOI] [PubMed] [Google Scholar]
  • 38.Watts RL. The role of dopamine agonists in early Parkinson’s disease. Neurology. 1997;49(1):S34–S48. doi: 10.1212/wnl.49.1_suppl_1.s34. [DOI] [PubMed] [Google Scholar]
  • 39.Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A. Bromocriptine in parkinsonism. Br Med J. 1974;4:442–444. doi: 10.1136/bmj.4.5942.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19:656–662. doi: 10.1002/mds.20201. [DOI] [PubMed] [Google Scholar]
  • 41.Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6:826–829. doi: 10.1016/S1474-4422(07)70218-1. [DOI] [PubMed] [Google Scholar]
  • 42.Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39–46. doi: 10.1056/NEJMoa054830. [DOI] [PubMed] [Google Scholar]
  • 43.Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol. 1996;312:35–44. doi: 10.1016/0014-2999(96)00454-2. [DOI] [PubMed] [Google Scholar]
  • 44.Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol. 1992;215:161–170. doi: 10.1016/0014-2999(92)90024-X. [DOI] [PubMed] [Google Scholar]
  • 45.Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564–566. doi: 10.1176/appi.ajp.161.3.564. [DOI] [PubMed] [Google Scholar]
  • 46.Lattanzi L, Dell’Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002;4:307–314. doi: 10.1034/j.1399-5618.2002.01171.x. [DOI] [PubMed] [Google Scholar]
  • 47.Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11:58–65. doi: 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  • 48.Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology. 1997;49(Suppl 1):S58–S62. doi: 10.1212/wnl.49.1_suppl_1.s58. [DOI] [PubMed] [Google Scholar]
  • 49.Brefel C, Thalamas C, Rayet S, et al. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol. 1998;45:412–415. doi: 10.1046/j.1365-2125.1998.t01-1-00704.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68:1262–1267. doi: 10.1212/01.wnl.0000259516.61938.bb. [DOI] [PubMed] [Google Scholar]
  • 51.Nisipeanu P, Korczyn AD. Dopamine agonists. In: Factor S, Weiner WJ, editors. Parkinson’s disease: diagnosis and clinical management. 2nd ed. New York: Demos; 2008. pp. 515–532. [Google Scholar]
  • 52.Guldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol. 2005;28:106–110. doi: 10.1097/01.wnf.0000162228.00154.ba. [DOI] [PubMed] [Google Scholar]
  • 53.Parkinson Study Group A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol. 2003;60:1721–1728. doi: 10.1001/archneur.60.12.1721. [DOI] [PubMed] [Google Scholar]
  • 54.Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951;56:251–253. [PubMed] [Google Scholar]
  • 55.LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004;62(Suppl 4):S8–S11. doi: 10.1212/wnl.62.6_suppl_4.s8. [DOI] [PubMed] [Google Scholar]
  • 56.Shannon KM, Bennett JP, Friedman JH, Pramipexole Study Group Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology. 1997;49:724–728. doi: 10.1212/wnl.49.3.724. [DOI] [PubMed] [Google Scholar]
  • 57.Parkinson Study Group Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA. 1997;278:125–130. doi: 10.1001/jama.278.2.125. [DOI] [PubMed] [Google Scholar]
  • 58.Adler CH, Sethi KD, Hauser RA, et al. Ropinirole Study Group. Ropinirole for the treatment of early Parkinson’s disease. Neurology. 1997;49:393–399. doi: 10.1212/wnl.49.2.393. [DOI] [PubMed] [Google Scholar]
  • 59.Sethi KD, O’Brien CF, Hammerstad JP, Ropinirole Study Group et al. Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Arch Neurol. 1998;55:1211–1216. doi: 10.1001/archneur.55.9.1211. [DOI] [PubMed] [Google Scholar]
  • 60.Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272–276. doi: 10.1212/01.wnl.0000252355.79284.22. [DOI] [PubMed] [Google Scholar]
  • 61.Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22:2398–2404. doi: 10.1002/mds.21741. [DOI] [PubMed] [Google Scholar]
  • 62.Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162–168. doi: 10.1212/wnl.49.1.162. [DOI] [PubMed] [Google Scholar]
  • 63.Guttman M, International Pramipexole—Bromocriptine Study Group Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology. 1997;49:1060–1065. doi: 10.1212/wnl.49.4.1060. [DOI] [PubMed] [Google Scholar]
  • 64.Lieberman A, Olanow CW, Sethi K, Ropinirole Study Group et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Neurology. 1998;51:1057–1062. doi: 10.1212/wnl.51.4.1057. [DOI] [PubMed] [Google Scholar]
  • 65.Poewe WH, Rascol O, Quinn N, SP 515 Investigators et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6:513–520. doi: 10.1016/S1474-4422(07)70108-4. [DOI] [PubMed] [Google Scholar]
  • 66.Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology. 2004;62(Suppl 4):S12–S17. doi: 10.1212/wnl.62.6_suppl_4.s12. [DOI] [PubMed] [Google Scholar]
  • 67.Dewey RB, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385–1392. doi: 10.1001/archneur.58.9.1385. [DOI] [PubMed] [Google Scholar]
  • 68.Pfeiffer RF, Gutmann L, Hull KL, Bottini PB, Sherry JH. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:93–100. doi: 10.1016/j.parkreldis.2006.06.012. [DOI] [PubMed] [Google Scholar]
  • 69.Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord. 1990;5:280–285. doi: 10.1002/mds.870050404. [DOI] [PubMed] [Google Scholar]
  • 70.Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908–1910. doi: 10.1212/wnl.52.9.1908. [DOI] [PubMed] [Google Scholar]
  • 71.Shapira A. Sleep attacks (sleep episodes) with pergolide. Lancet. 2000;355:1332–1333. doi: 10.1016/S0140-6736(00)02118-8. [DOI] [PubMed] [Google Scholar]
  • 72.Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes in Parkinson’s disease. Mov Disord. 2000;15:212–215. doi: 10.1002/1531-8257(200003)15:2<212::AID-MDS1002>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  • 73.Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord. 2000;15:658–663. doi: 10.1002/1531-8257(200007)15:4<658::AID-MDS1009>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  • 74.Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson’s disease: polysomnographic recordings. Mov Disord. 2001;16:500–506. doi: 10.1002/mds.1083. [DOI] [PubMed] [Google Scholar]
  • 75.Rye DB, Bliwise DL, Dihenia B, Gurecki P. Daytime sleepiness in Parkinson’s disease. J Sleep Res. 2000;9:63–69. doi: 10.1046/j.1365-2869.2000.00201.x. [DOI] [PubMed] [Google Scholar]
  • 76.Meindorfner C, Körner Y, Möller JC, Stiasny-Kolster K, Oertel WH, Krüger HP. Driving in Parkinson’s disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord. 2005;20:832–842. doi: 10.1002/mds.20412. [DOI] [PubMed] [Google Scholar]
  • 77.Hobson DE, Lang AE, Martin WRW, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson’s disease: a survey of the Canadian Movement Disorders Group. JAMA. 2002;287:455–463. doi: 10.1001/jama.287.4.455. [DOI] [PubMed] [Google Scholar]
  • 78.Avorn J, Schneeweiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005;62:1242–1248. doi: 10.1001/archneur.62.8.1242. [DOI] [PubMed] [Google Scholar]
  • 79.Adler CH, Thorpy MJ. Sleep issues in Parkinson’s disease. Neurology. 2005;64(Suppl 3):S12–S20. doi: 10.1212/wnl.64.12_suppl_3.s12. [DOI] [PubMed] [Google Scholar]
  • 80.Galpern WR, Stacy M. Management of impulse control disorders in Parkinson’s disease. Curr Treat Options Neurol. 2007;9:189–197. doi: 10.1007/BF02938408. [DOI] [PubMed] [Google Scholar]
  • 81.Kurlan R. Disabling repetitive behaviors in Parkinson’s disease. Mov Disord. 2004;19:433–437. doi: 10.1002/mds.10625. [DOI] [PubMed] [Google Scholar]
  • 82.Friedman JH. Punding on levodopa. Biol Psychiatry. 1994;36:350–351. doi: 10.1016/0006-3223(94)90636-X. [DOI] [PubMed] [Google Scholar]
  • 83.Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68:423–428. doi: 10.1136/jnnp.68.4.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989;12:375–383. doi: 10.1097/00002826-198910000-00002. [DOI] [PubMed] [Google Scholar]
  • 85.Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006;66:1750–1752. doi: 10.1212/01.wnl.0000218206.20920.4d. [DOI] [PubMed] [Google Scholar]
  • 86.Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000;15:869–872. doi: 10.1002/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  • 87.Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology. 2003;61:422–423. doi: 10.1212/01.wnl.0000076478.45005.ec. [DOI] [PubMed] [Google Scholar]
  • 88.Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377–1381. doi: 10.1001/archneur.62.9.noc50009. [DOI] [PubMed] [Google Scholar]
  • 89.Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006;67:1254–1257. doi: 10.1212/01.wnl.0000238503.20816.13. [DOI] [PubMed] [Google Scholar]
  • 90.Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63:969–973. doi: 10.1001/archneur.63.7.969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F. Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord. 2006;21:2068–2072. doi: 10.1002/mds.21072. [DOI] [PubMed] [Google Scholar]
  • 92.Morgan JC, Iyer SS, Sethi KD. Impulse control disorders and dopaminergic drugs. Arch Neurol. 2006;63:298–299. doi: 10.1001/archneur.63.2.298-b. [DOI] [PubMed] [Google Scholar]
  • 93.Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch Neurol. 2006;63:298–298. doi: 10.1001/archneur.63.2.298-a. [DOI] [PubMed] [Google Scholar]
  • 94.Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64:212–216. doi: 10.1001/archneur.64.2.212. [DOI] [PubMed] [Google Scholar]
  • 95.Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord 2007 Epub ahead of print; doi:10.1002/mds.21770. [DOI] [PMC free article] [PubMed]
  • 96.Gschwandtner U, Aston J, Renaud S, Fuhr P. Pathologic gambling in patients with Parkinson’s disease. Clin Neuropharmacol. 2001;24:170–172. doi: 10.1097/00002826-200105000-00009. [DOI] [PubMed] [Google Scholar]
  • 97.Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67:1258–1261. doi: 10.1212/01.wnl.0000238401.76928.45. [DOI] [PubMed] [Google Scholar]
  • 98.Imamura A, Uitti RJ, Wszolek ZK. Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinsonism Relat Disord. 2006;12:506–508. doi: 10.1016/j.parkreldis.2006.02.004. [DOI] [PubMed] [Google Scholar]
  • 99.Olanow CW, Tasmar Advisory Panel Tolcapone and hepatotoxic effects. Arch Neurol. 2000;57:263–267. doi: 10.1001/archneur.57.2.263. [DOI] [PubMed] [Google Scholar]
  • 100.Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review. Clin Neuropharmacol. 2007;30:287–294. doi: 10.1097/wnf.0b013e318038d2b6. [DOI] [PubMed] [Google Scholar]
  • 101.Jorga KM. COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin Neuropharmacol. 1998;21(suppl 1):S9–S16. [Google Scholar]
  • 102.Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61:1563–1568. doi: 10.1001/archneur.61.10.1563. [DOI] [PubMed] [Google Scholar]
  • 103.Waters CH, Kurth M, Bailey P, Tolcapone Stable Study Group et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Neurology. 1997;49:665–671. doi: 10.1212/wnl.49.3.665. [DOI] [PubMed] [Google Scholar]
  • 104.Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 1997;49:1066–1071. doi: 10.1212/wnl.49.4.1066. [DOI] [PubMed] [Google Scholar]
  • 105.Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997;63:421–428. doi: 10.1136/jnnp.63.4.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Parkinson Study Group Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol. 1997;42:747–755. doi: 10.1002/ana.410420511. [DOI] [PubMed] [Google Scholar]
  • 107.Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947–954. doi: 10.1016/S0140-6736(05)71083-7. [DOI] [PubMed] [Google Scholar]
  • 108.Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin Neuropharmacol. 2001;24:295–299. doi: 10.1097/00002826-200109000-00007. [DOI] [PubMed] [Google Scholar]
  • 109.Entacapone to Tolcapone Switch Study Investigators Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov Disord. 2007;22:14–19. doi: 10.1002/mds.21131. [DOI] [PubMed] [Google Scholar]
  • 110.Fisher A, Croft-Baker J, Davis M, Purcell P, McLean AJ. Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord. 2002;17:1362–1365. doi: 10.1002/mds.10342. [DOI] [PubMed] [Google Scholar]
  • 111.Lew MF, Kricorian G. Results from a 2-year centralized tolcapone liver enzyme monitoring program. Clin Neuropharmacol. 2007;30:281–286. doi: 10.1097/WNF.0b013e318149f290. [DOI] [PubMed] [Google Scholar]
  • 112.Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:944–948. doi: 10.1136/jnnp.2006.097154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Rajput A, Zesiewicz TA, Hauser RA. Monoamine oxidase inhibitors. In: Factor SA, Weiner WJ, editors. Parkinson’s disease: diagnosis and clinical management. 2nd ed. New York: Demos Medical Publishing; 2008. pp. 499–514. [Google Scholar]
  • 114.Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science. 1985;230:181–183. doi: 10.1126/science.3875898. [DOI] [PubMed] [Google Scholar]
  • 115.Parkinson Study Group Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1989;321:1364–1371. doi: 10.1056/NEJM198911163212004. [DOI] [PubMed] [Google Scholar]
  • 116.Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176–183. doi: 10.1056/NEJM199301213280305. [DOI] [PubMed] [Google Scholar]
  • 117.Golbe LI. Deprenyl as symptomatic therapy in Parkinson’s disease. Clin Neuropharmacol. 1988;11:387–400. doi: 10.1097/00002826-198810000-00001. [DOI] [PubMed] [Google Scholar]
  • 118.Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin Neuropharmacol. 1988;11:45–55. doi: 10.1097/00002826-198802000-00004. [DOI] [PubMed] [Google Scholar]
  • 119.Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after l-deprenyl (Selegeline) withdrawal. Synapse. 1994;18:86–93. doi: 10.1002/syn.890180203. [DOI] [PubMed] [Google Scholar]
  • 120.Siderowf A, Stern M. Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology. 2006;66(Suppl 4):S80–S88. doi: 10.1212/wnl.66.10_suppl_4.s80. [DOI] [PubMed] [Google Scholar]
  • 121.Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50:375–382. doi: 10.1111/j.2042-7158.1998.tb06876.x. [DOI] [PubMed] [Google Scholar]
  • 122.Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm. 2003;110:1241–1255. doi: 10.1007/s00702-003-0036-4. [DOI] [PubMed] [Google Scholar]
  • 123.Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426–432. doi: 10.1002/mds.20036. [DOI] [PubMed] [Google Scholar]
  • 124.Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and “wearing off” symptoms. Clin Neuropharmacol. 2007;30:295–300. doi: 10.1097/WNF.0b013e3180616570. [DOI] [PubMed] [Google Scholar]
  • 125.Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24:1295–1305. doi: 10.1592/phco.24.14.1295.43156. [DOI] [PubMed] [Google Scholar]
  • 126.Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937–1943. doi: 10.1001/archneur.59.12.1937. [DOI] [PubMed] [Google Scholar]
  • 127.Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561–566. doi: 10.1001/archneur.61.4.561. [DOI] [PubMed] [Google Scholar]
  • 128.Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241–248. doi: 10.1001/archneur.62.2.241. [DOI] [PubMed] [Google Scholar]
  • 129.deMarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21:1716–1721. doi: 10.1002/mds.21048. [DOI] [PubMed] [Google Scholar]
  • 130.Clarke A, Johnson ES, Mallard N, et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm. 2003;110:1257–1271. doi: 10.1007/s00702-003-0042-6. [DOI] [PubMed] [Google Scholar]
  • 131.Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology. 1995;45:219–223. doi: 10.1212/wnl.45.2.219. [DOI] [PubMed] [Google Scholar]
  • 132.Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–713. doi: 10.1176/ajp.148.6.705. [DOI] [PubMed] [Google Scholar]
  • 133.Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Neurology. 1997;48:1070–1077. doi: 10.1212/wnl.48.4.1070. [DOI] [PubMed] [Google Scholar]
  • 134.Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983–995. doi: 10.1212/01.wnl.0000215250.82576.87. [DOI] [PubMed] [Google Scholar]
  • 135.Colosimo C, Fabbrini G, Berardelli A. Drug insight: new drugs in development for Parkinson’s disease. Nat Clin Pract Neurol. 2006;2:600–610. doi: 10.1038/ncpneuro0340. [DOI] [PubMed] [Google Scholar]
  • 136.Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108–1115. doi: 10.1212/01.wnl.0000258660.74391.c1. [DOI] [PubMed] [Google Scholar]
  • 137.Bonuccelli U, Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology. 2006;67(Suppl 2):S30–S38. doi: 10.1212/wnl.67.7_suppl_2.s30. [DOI] [PubMed] [Google Scholar]
  • 138.Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology. 2006;67(Suppl 2):S24–S29. doi: 10.1212/wnl.67.7_suppl_2.s24. [DOI] [PubMed] [Google Scholar]
  • 139.Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(Suppl 2):S18–S23. doi: 10.1212/wnl.67.7_suppl_2.s18. [DOI] [PubMed] [Google Scholar]
  • 140.Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord. 1993;8:165–170. doi: 10.1002/mds.870080208. [DOI] [PubMed] [Google Scholar]
  • 141.Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease: long-term experience. Acta Neurol Scand. 2001;104:343–348. doi: 10.1034/j.1600-0404.2001.00153.x. [DOI] [PubMed] [Google Scholar]
  • 142.Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol. 2003;184:285–294. doi: 10.1016/S0014-4886(03)00250-4. [DOI] [PubMed] [Google Scholar]
  • 143.Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297–303. doi: 10.1212/01.wnl.0000081227.84197.0b. [DOI] [PubMed] [Google Scholar]
  • 144.Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Mov Disord. 2003;18:872–883. doi: 10.1002/mds.10464. [DOI] [PubMed] [Google Scholar]
  • 145.Adler CH, Singer C, O’Brien C, Tolcapone Fluctuator Study Group III et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa—carbidopa. Arch Neurol. 1998;55:1089–1095. doi: 10.1001/archneur.55.8.1089. [DOI] [PubMed] [Google Scholar]
  • 146.Myllylä VV, Jackson M, Larsen JP, Baas H, Tolcapone International Parkinson’s Disease Study (TIPS) Group I Efficacy and safety of tolcapone levodopa-treated Parkinson’s disease patients with “wearing-off” phenomenon: a multicentre, double-blind, randomized, placebo-controlled trial. Eur J Neurol. 1997;4:333–341. doi: 10.1111/j.1468-1331.1997.tb00358.x. [DOI] [Google Scholar]
  • 147.Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone Fluctuator Study Group I. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology. 1997;48:81–87. doi: 10.1212/wnl.48.1.81. [DOI] [PubMed] [Google Scholar]
  • 148.Rinne UK, Larsen JP, Siden A, Worm-Petersen J, Nomecomt Study Group Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 1998;51:1309–1314. doi: 10.1212/wnl.51.5.1309. [DOI] [PubMed] [Google Scholar]
  • 149.Fénelon G, Giménez-Roldán S, Montastruc JL, et al. Efficacy and tolerability of entacapone in patients with Parkinson’s disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations: a randomized, double-blind, multicentre study. J Neural Transm. 2003;110:239–251. doi: 10.1007/s00702-002-0799-z. [DOI] [PubMed] [Google Scholar]
  • 150.Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study Group Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen Study) Acta Neurol Scand. 2002;105:245–255. doi: 10.1034/j.1600-0404.2002.1o174.x. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES